We first used immunoblotting to confirm the expression of each of the individual PIM kinases in the metastatic hepatoblastoma cell line (Figure S1A), providing evidence for the presence of a druggable target for the pan-PIM inhibitor, AZD1208, which was employed in the remainder of our studies. This evidence concerns the gene PIM1 and hepatoblastoma.